Search
Search Results
-
Margetuximab: First Approval
The second-generation anti-human epidermal growth factor receptor2 protein (HER2) monoclonal antibody margetuximab (MARGENZA™, margetuximab-cmkb) is...
-
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Approximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed...
-
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the...
-
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage. The development of...
-
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
PurposeDespite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular...
-
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials
Gastric cancer (GC) is the one of the most commonly solid cancer worldwide. Although under the aggressive treatment, the poor clinical outcomes of...
-
Gastric cancer treatment: recent progress and future perspectives
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of...
-
Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments
Purpose of ReviewAlthough mortality rates have declined significantly in recent years, breast cancer remains the second most common cause of cancer...
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Amplification and/or overexpression of ERBB2 , the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an...
-
Clinical trial data and emerging strategies: HER2-positive breast cancer
A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the...
-
Molecular perspective on targeted therapy in breast cancer: a review of current status
Breast cancer is categorized at the molecular level according to the status of certain hormone and growth factor receptors, and this classification...
-
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation
PurposeOur goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA)...
-
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
IntroductionMany patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of...
-
Current status and future perspectives in HER2 positive advanced gastric cancer
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2...
-
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review
PurposeHuman epidermal growth factor receptor 2 (HER2)–targeted therapies improve survival for patients with HER2-positive breast cancer but carry...
-
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
PurposeStandard-of-care for HER2-positive metastatic breast cancer (HER2 + mBC) patients consists of trastuzumab ± pertuzumab with chemotherapy in...
